Filing Details

Accession Number:
0001493152-21-032035
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-20 16:15:18
Reporting Period:
2021-12-20
Accepted Time:
2021-12-20 16:15:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1873835 Immix Biopharma Inc. IMMX Pharmaceutical Preparations (2834) 454869378
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1889967 S Gabriel Morris C/O Immix Biopharma, Inc.
11400 West Olympic Blvd., Suite 200
Los Angeles CA 90064
Chief Financial Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-12-20 74,116 $0.85 74,116 No 4 C Direct
Common Stock Acquisiton 2021-12-20 123,527 $0.85 123,527 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-12-20 123,176 $0.85 246,703 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-12-20 2,000 $5.00 76,116 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Convertible Note Disposition 2021-12-20 0 $0.00 74,116 $0.85
Common Stock Convertible Note Disposition 2021-12-20 0 $0.00 123,527 $0.85
Common Stock Convertible Note Disposition 2021-12-20 0 $0.00 123,176 $0.85
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. On March 18, 2021, the Registrant issued the Reporting Person a note in the amount of $60,000 which is payable upon request of the majority holders of like tenure notes on or after March 1, 2023. Pursuant to the terms of the note, because the Registrant sold equity securities in its initial public offering resulting in proceeds of at least $10 million, the note automatically converted into shares of the Registrant's common stock.
  2. On March 18, 2021, the Registrant issued Alwaysraise LLC a note in the amount of $100,000 which is payable upon request of the majority holders of like tenure notes on or after March 1, 2023. Pursuant to the terms of the note, because the Registrant sold equity securities in its initial public offering resulting in proceeds of at least $10 million, the note automatically converted into shares of the Registrant's common stock.
  3. Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity.
  4. On April 2, 2021, the Registrant issued Alwaysraise a note in the amount of $100,000 which is payable upon request of the majority holders of like tenure notes on or after March 1, 2023. Pursuant to the terms of the note, because the Registrant sold equity securities in its initial public offering resulting in proceeds of at least $10 million, the note automatically converted into shares of the Registrant's common stock.